Sector News

Global green light for Merck KGaA/Sigma merger

August 12, 2015
Life sciences
Merck KGaA has been granted unconditional permission by regulatory authorities in Brazil to purchase US life sciences group Sigma-Aldrich, which means the firm has now secured approvals from all relevant jurisdictions for its planned acquisition.
 
The German drugmaker said it expects to complete the transaction sometime in the third quarter of this year, creating a business with combined sales of 4.7 billion euros (based on 2013 financials).
 
The timeframe for deal completion has been slightly extended to allow commitments made to the European Commission under its conditional approval of the deal – i.e. the sale of parts of Sigma-Aldrich’s solvents and inorganics business in the region – to be met.
 
The companies first unveiled their $17 billion merger in September last year, in a move to establish “one of the leading players in the $130 billion global life science industry,” with the ability to offer customers “a highly attractive set of established brands and an efficient supply chain that can support the delivery of more than 300,000 products”, according to Merck.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach